{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.8","upperLimit":"59.3","value":"54.1"}]}],"title":"Patient-level CDR - Central Reader 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.1","upperLimit":"56.6","value":"51.4"}]}],"title":"Patient-level CDR - Central Reader 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.4","upperLimit":"56.9","value":"51.6"}]}],"title":"Patient-level CDR - Central Reader 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.0","upperLimit":"50.3","value":"46.2"}]}],"title":"Region-level PPV - Central Reader 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55.1","upperLimit":"65.5","value":"60.3"}]}],"title":"Region-level PPV - Central Reader 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47.6","upperLimit":"57.5","value":"52.6"}]}],"title":"Region-level PPV - Central Reader 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"366"}],"units":"Participants"}],"description":"The CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any coexisting FP findings. When determining the region-level PPV, all rhPSMA7.3 (18F) PET-positive regions (maximum of three per patient) were categorized as TP or FP regions using histopathology or imaging.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients who received rhPSMA-7.3 (18F) injection followed by a PET/CT scan and for whom sufficient data are available to permit a clear classification following the SoT algorithm.","id":"OG000","title":"Efficacy Analysis Population (EAP)"}],"paramType":"NUMBER","populationDescription":"Patients who received rhPSMA-7.3 (18F) injection followed by a PET/CT scan and for whom sufficient data are available to permit a clear classification following the SoT algorithm.","reportingStatus":"POSTED","timeFrame":"Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan","title":"Patient-level CDR and Region-level PPV of rhPSMA7.3 (18F) PET for BCR of Prostate Cancer Using Histopathology or Imaging as a SoT","type":"PRIMARY","unitOfMeasure":"percentage"}